A large population affected by severe eosinophilic asthma increases the need for targeted biologics like Benralizumab.
The U.S. Benralizumab Drug Market was valued at USD 1,049 Million in 2024 and is projected to reach USD 1,816 Billion by 2030, with a compound annual growth rate (CAGR) of 9.71% from 2025 to 2030.
The global Benralizumab drug market is currently led by the United States, primarily due to a combination of high disease prevalence, advanced healthcare infrastructure, and early adoption of innovative biologic therapies. Benralizumab (marketed as Fasenra), a monoclonal antibody used for severe eosinophilic asthma, has gained significant traction in the U.S., supported by favorable reimbursement policies, established clinical use, and extensive physician awareness. This strong uptake drives a large share of global revenue, with North America overall accounting for the largest portion of the market.
Factors such as robust regulatory support from the U.S. Food and Drug Administration (FDA), high healthcare spending, and widespread insurance coverage further reinforce the U.S.’s leadership position. These elements make Benralizumab more accessible and widely prescribed compared with many other regions, helping the U.S. remain the dominant force in this specialized drug market.
1. The U.S. has a large patient population with eosinophilic asthma, increasing demand for targeted biologics like Benralizumab.
The United States has one of the highest rates of asthma in the world, with many patients struggling with a particularly severe form known as eosinophilic asthma. This type can be tough to control, even with standard inhalers, leading to frequent flare-ups, declining lung function, and a heavy dependency on oral corticosteroids, which can have serious side effects over time. As doctors become better at recognizing eosinophilic asthma, more patients are eligible for advanced treatments like Benralizumab. This shift is creating a strong and ongoing demand for therapies that directly target eosinophilic inflammation.
Patients in the U.S. also have access to specialized care, with numerous clinics focused on pulmonary and allergy issues, better equipping them to diagnose and manage severe asthma cases. As healthcare moves towards personalized medicine, medications like Benralizumab are gaining attention for their specific targeting abilities and their documented success in reducing asthma attacks and enhancing patients' quality of life. These factors are key to the U.S. leading the Benralizumab market globally.
2. Well-developed medical facilities and rapid adoption of innovative treatments support strong Benralizumab uptake.
The U.S. healthcare system features world-class hospitals, specialized respiratory centers, and highly trained specialists who can evaluate and treat severe asthma using advanced biologic drugs. This strong infrastructure allows for rapid clinical adoption of innovative therapies such as Benralizumab. Unlike many countries where access to biologics is limited by hospital capacity or physician training, the U.S. has an established network of providers familiar with administering monoclonal antibodies and monitoring patient outcomes. In addition, the presence of large pharmaceutical companies, research institutions, and clinical trial networks accelerates the dissemination of new treatment guidelines and clinical evidence. As a result, physicians in the U.S. are often among the earliest adopters of biologic therapies, supported by extensive training programs, medical conferences, and continuing education. Patients also have more touchpoints with specialists who can recommend biologics when standard therapies fail. This environment of technological readiness, clinical confidence, and research engagement fuels high Benralizumab utilization and maintains the U.S. at the forefront of biologics adoption in respiratory care.
3. Favorable insurance and reimbursement systems make costly biologics more affordable for patients.
One of the biggest factors driving the U.S. Benralizumab market is the presence of strong reimbursement frameworks through both private insurance and federal programs such as Medicare and Medicaid. Biologic medications are expensive, and affordability is often a barrier in many parts of the world. However, U.S. insurers commonly cover Benralizumab for patients who meet clinical criteria, significantly reducing out-of-pocket expenses. This lowers financial barriers and expands access for a broader patient population. Manufacturers also provide patient assistance programs that reduce copays or offer support during coverage gaps, further encouraging continued therapy. The supportive reimbursement environment helps physicians prescribe Benralizumab with confidence, knowing that most patients will be able to access and maintain treatment. Strong payer support is particularly crucial for chronic conditions like severe eosinophilic asthma, where long-term treatment continuity is essential for effectiveness. As healthcare plans increasingly recognize the cost savings from reduced hospitalizations and emergency visits, they further streamline coverage for biologics, reinforcing the U.S.’s market leadership.
4. U.S. pulmonologists and allergists are highly familiar with biologic therapies, leading to higher prescribing rates.
U.S. pulmonologists, allergists, and immunologists have high levels of awareness regarding severe eosinophilic asthma and the role of targeted biologics like Benralizumab. This clinical sophistication stems from consistent exposure to medical conferences, peer-reviewed research, pharmaceutical detailing, and guideline updates from organizations such as the Global Initiative for Asthma (GINA). Because Benralizumab is a highly targeted therapy, proper patient selection is essential—and U.S. specialists are equipped with advanced diagnostic tools, biomarkers testing, and educational resources to identify ideal candidates. Additionally, U.S. physicians actively participate in multicenter clinical trials, giving them early experience with emerging treatments and reinforcing confidence in prescribing FDA-approved biologics. The culture of evidence-based practice, combined with frequent specialist-patient interactions, promotes timely adoption of advanced therapies. U.S. clinicians also tend to follow step-up asthma management strategies closely, enabling them to recognize when standard treatments are insufficient and a biologic is appropriate. This high clinical vigilance and familiarity significantly boost Benralizumab utilization.
5. Clear regulatory pathways and post-approval support encourage widespread clinical use and market growth.
The U.S. Food and Drug Administration (FDA) maintains a structured and well-defined pathway for the approval of biologic drugs, emphasizing safety, efficacy, and post-marketing surveillance. This regulatory clarity encourages pharmaceutical companies to invest in the U.S. market and launch biologics like Benralizumab with confidence. The FDA also provides accelerated review pathways, breakthrough therapy designations, and ongoing monitoring programs that support the introduction and sustained use of advanced therapies. Once approved, the FDA collaborates with healthcare providers and manufacturers to ensure proper labeling, safety reporting, and real-world evidence collection, reinforcing trust in biologics. Furthermore, U.S. regulatory frameworks support the continued refinement of treatment guidelines and encourage innovation in asthma care. As a result, the environment enables rapid patient access to cutting-edge therapies, strengthens physician confidence, and contributes to the U.S.’s dominant role in the global Benralizumab drug market.
Competitive Landscape
Some of the major companies operating within the Benralizumab Drug market are: AstraZeneca, Others.